Overview Dividends

(CPRX) Catalyst Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14888U1016

Firdapse, Fycompa, Ruzurgi, Agamree

CPRX EPS (Earnings per Share)

EPS (Earnings per Share) of CPRX over the last years for every Quarter: "2020-09": 0.11, "2020-12": 0.11, "2021-03": 0.07, "2021-06": 0.11, "2021-09": 0.1, "2021-12": 0.09, "2022-03": 0.12, "2022-06": 0.2, "2022-09": 0.2, "2022-12": 0.22, "2023-03": 0.26, "2023-06": 0.53, "2023-09": -0.29, "2023-12": 0.31, "2024-03": 0.19, "2024-06": 0.33, "2024-09": 0.35, "2024-12": 0.7, "2025-03": 0.68, "2025-06": 0.68, "2025-09": 0.68,
EPS Growth (3Y CAGR): 50.73%
EPS Trend (3Y Correlation): 64.0%

CPRX Revenue

Revenue of CPRX over the last years for every Quarter: 2020-09: 29.317, 2020-12: 31.014909, 2021-03: 30.205, 2021-06: 36.365, 2021-09: 35.954, 2021-12: 38.309, 2022-03: 43.089, 2022-06: 53.113, 2022-09: 57.244, 2022-12: 60.757, 2023-03: 85.366, 2023-06: 99.582, 2023-09: 102.688, 2023-12: 110.568, 2024-03: 98.509, 2024-06: 122.71, 2024-09: 128.695, 2024-12: 141.82, 2025-03: 141.421, 2025-06: 146.563, 2025-09: 148.392,
Revenue Growth (3Y CAGR): 38.36%
Revenue Trend (3Y Correlation): 92.3%
Risk via 10d forecast
Volatility 41.6%
Value at Risk 5%th 62.2%
Reward
Sharpe Ratio 0.02
Alpha Jensen -16.87
Character
Hurst Exponent 0.433
Beta 0.688
Drawdowns 3y
Max DD 45.37%
Mean DD 20.49%

Description: CPRX Catalyst Pharmaceuticals November 10, 2025

Catalyst Pharmaceuticals (NASDAQ: CPRX) is a commercial-stage biopharma that targets rare diseases in the U.S., leveraging a small-capsized portfolio to generate high-margin specialty revenues.

The company’s marketed products include Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), Fycompa (an AMPA-receptor antagonist for focal-onset and tonic-clonic seizures), Ruzurgi (a pediatric LEMS indication, launched in 2023), and AGAMREE (a corticosteroid under investigation for Duchenne muscular dystrophy.

As of the latest Q2 2024 filing, CPRX reported net product revenue of $210 million, a cash balance of $340 million, and a runway extending roughly 18 months absent additional financing, reflecting the cash-intensive nature of rare-disease commercialization.

Key sector drivers that shape CPRX’s outlook include the U.S. orphan-drug premium pricing framework (average 5-year price increase of ~12 % in the rare-disease segment), ongoing FDA incentives for accelerated approvals, and a competitive landscape where generic entry risk is mitigated by strong patent protection on its flagship assets.

For a deeper quantitative dive into CPRX’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.

CPRX Stock Overview

Market Cap in USD 2,629m
Sub-Industry Biotechnology
IPO / Inception 2006-11-08
Return 12m vs S&P 500 -14.7%
Analyst Rating 4.86 of 5

CPRX Dividends

Currently no dividends paid

CPRX Growth Ratios

CAGR 14.51%
CAGR/Max DD Calmar Ratio 0.32
CAGR/Mean DD Pain Ratio 0.71
Current Volume 1373.5k
Average Volume 1286.9k

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (217.6m TTM) > 0 and > 6% of Revenue (6% = 34.7m TTM)
FCFTA 0.22 (>2.0%) and ΔFCFTA -2.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 125.2% (prev 94.16%; Δ 31.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.22 (>3.0%) and CFO 234.7m > Net Income 217.6m (YES >=105%, WARN >=100%)
Net Debt (-687.4m) to EBITDA (290.1m) ratio: -2.37 <= 3.0 (WARN <= 3.5)
Current Ratio 6.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (127.1m) change vs 12m ago 1.34% (target <= -2.0% for YES)
Gross Margin 84.06% (prev 86.32%; Δ -2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 63.41% (prev 59.65%; Δ 3.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.17 (EBITDA TTM 290.1m / Interest Expense TTM -90.3m) >= 6 (WARN >= 3)

Altman Z'' 10.91

(A) 0.69 = (Total Current Assets 852.5m - Total Current Liabilities 128.7m) / Total Assets 1.05b
(B) 0.42 = Retained Earnings (Balance) 446.8m / Total Assets 1.05b
(C) 0.21 = EBIT TTM 195.5m / Avg Total Assets 911.8m
(D) 3.40 = Book Value of Equity 446.9m / Total Liabilities 131.4m
Total Rating: 10.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 91.05

1. Piotroski 4.0pt = -1.0
2. FCF Yield 12.08% = 5.0
3. FCF Margin 40.56% = 7.50
4. Debt/Equity 0.00 = 2.50
5. Debt/Ebitda -2.37 = 2.50
6. ROIC - WACC (= 9.79)% = 12.23
7. RoE 26.39% = 2.20
8. Rev. Trend 92.29% = 6.92
9. EPS Trend 64.05% = 3.20

What is the price of CPRX shares?

As of November 13, 2025, the stock is trading at USD 22.78 with a total of 1,373,488 shares traded.
Over the past week, the price has changed by +6.55%, over one month by +11.67%, over three months by +12.00% and over the past year by -1.13%.

Is Catalyst Pharmaceuticals a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Catalyst Pharmaceuticals (NASDAQ:CPRX) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 91.05 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CPRX is around 22.58 USD . This means that CPRX is currently overvalued and has a potential downside of -0.88%.

Is CPRX a buy, sell or hold?

Catalyst Pharmaceuticals has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy CPRX.
  • Strong Buy: 6
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CPRX price?

Issuer Target Up/Down from current
Wallstreet Target Price 34.9 53%
Analysts Target Price 34.9 53%
ValueRay Target Price 25.2 10.6%

CPRX Fundamental Data Overview November 10, 2025

Market Cap USD = 2.63b (2.63b USD * 1.0 USD.USD)
P/E Trailing = 12.5088
P/E Forward = 9.9701
P/S = 4.5471
P/B = 2.9796
Beta = 0.688
Revenue TTM = 578.2m USD
EBIT TTM = 195.5m USD
EBITDA TTM = 290.1m USD
Long Term Debt = 3.19m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 402.0k USD (from shortTermDebt, last fiscal year)
Debt = 2.46m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -687.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.94b USD (2.63b + Debt 2.46m - CCE 689.9m)
Interest Coverage Ratio = -2.17 (Ebit TTM 195.5m / Interest Expense TTM -90.3m)
FCF Yield = 12.08% (FCF TTM 234.5m / Enterprise Value 1.94b)
FCF Margin = 40.56% (FCF TTM 234.5m / Revenue TTM 578.2m)
Net Margin = 37.63% (Net Income TTM 217.6m / Revenue TTM 578.2m)
Gross Margin = 84.06% ((Revenue TTM 578.2m - Cost of Revenue TTM 92.2m) / Revenue TTM)
Gross Margin QoQ = 84.73% (prev 79.56%)
Tobins Q-Ratio = 1.85 (Enterprise Value 1.94b / Total Assets 1.05b)
Interest Expense / Debt = 69.24% (Interest Expense 1.70m / Debt 2.46m)
Taxrate = 25.69% (18.3m / 71.0m)
NOPAT = 145.3m (EBIT 195.5m * (1 - 25.69%))
Current Ratio = 6.62 (Total Current Assets 852.5m / Total Current Liabilities 128.7m)
Debt / Equity = 0.00 (Debt 2.46m / totalStockholderEquity, last quarter 920.2m)
Debt / EBITDA = -2.37 (Net Debt -687.4m / EBITDA 290.1m)
Debt / FCF = -2.93 (Net Debt -687.4m / FCF TTM 234.5m)
Total Stockholder Equity = 824.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.69% (Net Income 217.6m / Total Assets 1.05b)
RoE = 26.39% (Net Income TTM 217.6m / Total Stockholder Equity 824.5m)
RoCE = 23.62% (EBIT 195.5m / Capital Employed (Equity 824.5m + L.T.Debt 3.19m))
RoIC = 18.33% (NOPAT 145.3m / Invested Capital 792.6m)
WACC = 8.54% (E(2.63b)/V(2.63b) * Re(8.55%) + (debt cost/tax rate unavailable))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.70%
[DCF Debug] Terminal Value 79.81% ; FCFE base≈215.9m ; Y1≈266.4m ; Y5≈454.5m
Fair Price DCF = 57.05 (DCF Value 7.01b / Shares Outstanding 122.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 64.05 | EPS CAGR: 50.73% | SUE: 2.51 | # QB: 6
Revenue Correlation: 92.29 | Revenue CAGR: 38.36% | SUE: 2.93 | # QB: 5

Additional Sources for CPRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle